Key facts
- Trial Library’s last known valuation is $55.0M (Dec 2025).
- It has raised $17.0M; the latest was Early Stage VC ($10.0M) in Dec 2025.
- Notable investors include Plug and Play Tech Center, Gaingels, Lux Capital, Karman Ventures, Sterling Road — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Trial Library
- ·The full record, as it builds
Funding rounds
No funding rounds for Trial Library are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trial Library
Developer of clinical trial technology designed to improve health equity by expanding access to cancer precision medicine. The company's technology recognizes that inclusive research environments can answer questions that improve health outcomes and transform the standard of care by addressing inequities in discovery and access to cancer clinical trials, enabling customers to have assistance for accelerating equitable recruitment to clinical trials.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 30
- Website
- triallibrary.com/
- Ownership
- Privately Held (backing)
Trial Library doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trial Library shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trial Library in its N-PORT filings yet. We sweep new filings monthly.